Proteomics reveals differentially regulated pathways when comparing grade 2 and 4 astrocytomas

PLoS One. 2023 Nov 15;18(11):e0290087. doi: 10.1371/journal.pone.0290087. eCollection 2023.

Abstract

Astrocytic tumors are known for their high progression capacity and high mortality rates; in this regard, proteins correlated to prognosis can aid medical conduct. Although several genetic changes related to progression from grade 2 to grade 4 astrocytoma are already known, mRNA copies do not necessarily correlate with protein abundance and therefore could shadow further comprehension about this tumor's biology. This motivates us to seek for complementary strategies to study tumor progression at the protein level. Here we compare the proteomic profile of biopsies from patients with grade 2 (diffuse, n = 6) versus grade 4 astrocytomas (glioblastomas, n = 10) using shotgun proteomics. Data analysis performed with PatternLab for proteomics identified 5,206 and 6,004 proteins in the 2- and 4-grade groups, respectively. Our results revealed seventy-four differentially abundant proteins (p < 0.01); we then shortlist those related to greater malignancy. We also describe molecular pathways distinctly activated in the two groups, such as differences in the organization of the extracellular matrix, decisive both in tumor invasiveness and in signaling for cell division, which, together with marked contrasts in energy metabolism, are determining factors in the speed of growth and dissemination of these neoplasms. The degradation pathways of GABA, enriched in the grade 2 group, is consistent with a favorable prognosis. Other functions such as platelet degranulation, apoptosis, and activation of the MAPK pathway were correlated to grade 4 tumors and, consequently, unfavorable prognoses. Our results provide an important survey of molecular pathways involved in glioma pathogenesis for these histopathological groups.

MeSH terms

  • Astrocytoma* / pathology
  • Brain Neoplasms* / pathology
  • Glioblastoma* / pathology
  • Humans
  • Proteins
  • Proteomics
  • Signal Transduction

Substances

  • Proteins

Grants and funding

JSGF received a scholarship from covenant APU / PUCPR 28/2021 (Fundação Araucária); Carlos Chagas Institute (Fiocruz Paraná) for reagents and infrastructure support. We also acknowledge the grant PEP-ICC-008-FIO-21 from Fiocruz. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.